Cadila Healthcare today said it has received Establishment Inspection Report (EIR) for Baddi manufacturing plant from the US health regulator after successful completion of inspection.
The company’s “manufacturing plant at Baddi, Himachal Pradesh, has successfully obtained the Establishment Inspection Report from the United States Food and Drug Administration (USFDA)”, Cadila Healthcare said in a BSE filing.
This will now pave the way for further approval of products from this site, it added. The company makes formulations at its Baddi manufacturing facility.
Establishment Inspection Report is given to an establishment after the completion of the inspection by the FDA.
Cadila Healthcare shares were trading higher by 2.42 per cent at Rs 317.55 on the BSE.